Top health-care stocks:
Health-care shares were mainly higher in pre-market trade Thursday.
In health-care stock news, Eli Lilly ( LLY ) and Merck ( MRK ) Thursday reported an extension of a collaboration on safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal phase 3 study in first-line nonsquamous non-small cell lung cancer (NSCLC). Eli Lilly stock shares were flat in pre-market trading , and closed at $83.65 yesterday, in the top half of the 52-week range of $66.56 - $92.85. Merck shares were up 1% in pre-bell at $54.23, within the 52-week range of $45.69 - $63.62
Athersys ( ATHX ) Thursday reported that that multi-potent adult progenitor cells used in Athersys cell therapy currently in clinical development, are effective in improving the health of rodents after acute spinal cord injury. Shares, flat in pre-bell, closed at $1.01 yesterday, on the bottom of the 52-week range of $0.90 - $3.43 per unit.
AMAG Pharmaceuticals ( AMAG ) fell in pre-market trading after the U.S. Food and Drug Administration said the company's single-dose vial of Makena cannot be approved in its current form. In a complete response letter the FDA requested more information on Makena, a drug to reduce the risk of preterm birth in certain at-risk patients. Shares of AMAG fell 11% in pre-bell trading to a 52-week low of $25.87. The stock's 52-week range before today was $27.44 - $77.73.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.